Veracyte is trading 4.89% lower at $45.34 on October 6, 2026, with no confirmed company announcement directly explaining the decline.
- Recent coverage points to Decipher prostate-test data presented at ASTRO 2026, but does not establish that the data caused the drop.
- The broader market is higher, while the provided sector context shows biotech down 2.50%; industry weakness may be relevant but does not confirm the cause.